Clifton C. Mo

789 total citations
44 papers, 489 citations indexed

About

Clifton C. Mo is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Clifton C. Mo has authored 44 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 22 papers in Molecular Biology and 20 papers in Oncology. Recurrent topics in Clifton C. Mo's work include Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (15 papers) and CAR-T cell therapy research (7 papers). Clifton C. Mo is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (15 papers) and CAR-T cell therapy research (7 papers). Clifton C. Mo collaborates with scholars based in United States, Spain and Italy. Clifton C. Mo's co-authors include Judith E. Karp, Christopher S. Hourigan, Paul G. Richardson, Jacob P. Laubach, Omar Nadeem, Adam S. Sperling, Ola Landgren, Shonali Midha, Elizabeth O’Donnell and Dickran Kazandjian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Clifton C. Mo

42 papers receiving 480 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clifton C. Mo United States 11 242 216 177 73 69 44 489
Sophie Rigaudeau France 11 238 1.0× 125 0.6× 165 0.9× 66 0.9× 137 2.0× 22 558
Yogesh Jethava United States 10 249 1.0× 206 1.0× 151 0.9× 38 0.5× 53 0.8× 50 423
Angelo Belotti Italy 14 312 1.3× 245 1.1× 201 1.1× 55 0.8× 82 1.2× 41 451
Hyewon Lee South Korea 12 220 0.9× 127 0.6× 150 0.8× 62 0.8× 88 1.3× 38 424
Bachar Samra United States 9 150 0.6× 97 0.4× 136 0.8× 39 0.5× 38 0.6× 18 364
Anna Pawłowska United States 11 125 0.5× 124 0.6× 95 0.5× 33 0.5× 65 0.9× 44 465
Rabin Niroula United States 6 120 0.5× 119 0.6× 58 0.3× 35 0.5× 44 0.6× 23 284
Masashi Sawa Japan 14 456 1.9× 158 0.7× 149 0.8× 29 0.4× 77 1.1× 94 646
Anne‐Marie Langevin United States 12 95 0.4× 103 0.5× 113 0.6× 43 0.6× 32 0.5× 29 518
Giambattista Bertani Italy 8 302 1.2× 188 0.9× 70 0.4× 42 0.6× 103 1.5× 20 460

Countries citing papers authored by Clifton C. Mo

Since Specialization
Citations

This map shows the geographic impact of Clifton C. Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clifton C. Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clifton C. Mo more than expected).

Fields of papers citing papers by Clifton C. Mo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clifton C. Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clifton C. Mo. The network helps show where Clifton C. Mo may publish in the future.

Co-authorship network of co-authors of Clifton C. Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Clifton C. Mo. A scholar is included among the top collaborators of Clifton C. Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clifton C. Mo. Clifton C. Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mo, Clifton C., Houry Leblebjian, Eileen Regan, et al.. (2025). Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma. European Journal Of Haematology. 114(6). 982–989. 1 indexed citations
2.
Mo, Clifton C., et al.. (2025). SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 775–787.
3.
Mo, Clifton C., Francesco Corrado, Mehmet H. Kocoglu, et al.. (2025). Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19. Biomolecules. 15(7). 1004–1004. 1 indexed citations
4.
Mo, Clifton C., et al.. (2024). Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma. Cancers. 16(6). 1166–1166. 8 indexed citations
5.
Kocoglu, Mehmet H., Paul G. Richardson, Clifton C. Mo, Aaron P. Rapoport, & Djordje Atanackovic. (2024). Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses. Haematologica. 109(7). 2372–2377. 2 indexed citations
6.
O’Donnell, Elizabeth, Clifton C. Mo, Andrew J. Yee, et al.. (2024). Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial. The Lancet Haematology. 11(6). e415–e424. 8 indexed citations
7.
Mo, Clifton C., Francesco Corrado, Mehmet H. Kocoglu, et al.. (2024). Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide. Blood Reviews. 66. 101218–101218. 5 indexed citations
8.
Mo, Clifton C., Rebekah L. Wilson, M. Pérez, et al.. (2024). Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols. 13. e64905–e64905. 1 indexed citations
9.
10.
O’Donnell, Elizabeth, Clifton C. Mo, Andrew J. Yee, et al.. (2023). A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial). Blood. 142(Supplement 1). 4671–4671. 2 indexed citations
11.
Mo, Clifton C., Andrew J. Yee, Shonali Midha, et al.. (2023). Selinexor: Targeting a novel pathway in multiple myeloma. SHILAP Revista de lepidopterología. 4(3). 792–810. 17 indexed citations
12.
13.
Liu, Xili, Seungeun Oh, Wonshik Choi, et al.. (2023). Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs. Clinical and Experimental Medicine. 23(7). 3821–3832. 2 indexed citations
14.
Nadeem, Omar, Robert Redd, Clifton C. Mo, et al.. (2023). P-099 Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S89–S89. 1 indexed citations
15.
DeStefano, Christin B., Steven J. Gibson, Adam S. Sperling, et al.. (2022). The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology. 49(1). 19–26. 4 indexed citations
16.
O’Donnell, Elizabeth, Clifton C. Mo, Omar Nadeem, et al.. (2022). A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial). Blood. 140(Supplement 1). 7282–7283. 2 indexed citations
17.
Maurer, Katie, Haesook T. Kim, Utkarsh Acharya, et al.. (2021). COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances. 5(3). 861–871. 24 indexed citations
18.
Kwok, Mary, Shengyang Wu, Clifton C. Mo, Thomas A. Summers, & Mark Roschewski. (2016). Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas. Current Treatment Options in Oncology. 17(9). 47–47. 21 indexed citations
19.
Korde, Neha, Yong Zhang, Kelsey B. Loeliger, et al.. (2016). Monoclonal gammopathy‐associated pure red cell aplasia. British Journal of Haematology. 173(6). 876–883. 10 indexed citations
20.
Mo, Clifton C., Ndegwa Njuguna, Paul V. Beum, et al.. (2013). Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Haematologica. 98(8). 1259–1263. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sophie Rigaudeau Breakdown of academic impact, for papers by Yogesh Jethava Breakdown of academic impact, for papers by Angelo Belotti Breakdown of academic impact, for papers by Hyewon Lee Breakdown of academic impact, for papers by Bachar Samra Breakdown of academic impact, for papers by Anna Pawłowska Breakdown of academic impact, for papers by Rabin Niroula Breakdown of academic impact, for papers by Masashi Sawa Breakdown of academic impact, for papers by Anne‐Marie Langevin Breakdown of academic impact, for papers by Giambattista Bertani
Rankless by CCL
2026